Sanofi in­tro­duces Auba­gio for MS treat­ment

BioSpectrum (India) - - COMPANY NEWS -

Sanofi Gen­zyme, the spe­cialty care global busi­ness unit of Sanofi, brings to In­dia Auba­gio, from its in­ter­na­tional Mul­ti­ple Scle­ro­sis (MS) port­fo­lio. A chronic and de­bil­i­tat­ing dis­ease of the ner­vous sys­tem, Mul­ti­ple Scle­ro­sis has var­ied symp­toms like weak­ness in the limbs, poor vi­sion, fa­tigue or slurred speech. Auba­gio (Ter­i­fluno­mide, 14 mg) is the first orig­i­nal ‘once-daily’ oral ‘dis­ease mod­i­fy­ing ther­apy’ (DMT) for Mul­ti­ple Scle­ro­sis to be ap­proved in In­dia. It of­fers an ef­fec­tive, safe and a con­ve­nient op­tion that is in­di­cated as a first-line treat­ment for re­laps­ing forms of Mul­ti­ple Scle­ro­sis that must be taken once a day, with or with­out food. First ap­proved by the US FDA in 2012, Auba­gio has a strong global pres­ence to­day with ap­provals in more than 81 coun­tries. It has been ex­ten­sively stud­ied in more than 5,500 pa­tients with up to 13 years of clin­i­cal and fol­low-up stud­ies with proven clin­i­cal ef­fi­cacy, safety and tol­er­a­bil­ity out­comes. Glob­ally, more than 85,000 pa­tients with Mul­ti­ple Scle­ro­sis are ben­e­fit­ting from the use of Auba­gio.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.